CAMBRIDGE, MA — Sionna Therapeutics is reducing its workforce by 46% as it concentrates on a dual combination cystic fibrosis program and tries to stretch its cash runway. The restructuring, disclosed in an SEC filing, also includes the departure of Chief Business Officer Caroline Stark Beer, whose termination was effective Tuesday.
The company is keeping employees tied to the dual combination effort, which centers on SION-451 and SION-2222. Chief Medical Officer Charlotte McKee is also taking on the added role of research and development head, with no change to her compensation.
The move marks a sharp reset for the Massachusetts biotech after a difficult year of development setbacks and rising pressure to make its capital last longer.
Sionna shifts nearly all resources to its dual combination program
The company says the cost cuts are meant to push SION-451 and SION-2222 into a Phase 2a proof-of-concept trial. That combination is now Sionna’s only active program in development, according to its online pipeline.
By narrowing the company’s focus, Sionna is aiming to direct money, staff and management attention toward the programs it believes have the strongest chance of advancing. The filing makes clear that the reorganization is part of a broader effort to conserve resources while continuing development.
For employees who remain, the work will center on the cystic fibrosis combination strategy rather than a wider internal pipeline. The company has not provided a detailed breakdown of which roles were eliminated beyond the executive departure and the overall cut to headcount.
Phase 2a failure helped trigger the restructuring
Sionna’s decision follows the failure of a Phase 2a trial for SION-719 as an add-on to standard cystic fibrosis care. That result changed the company’s internal calculations about where to place its bets.
With SION-719 no longer driving the pipeline, the dual combination approach became the remaining development focus. The company’s pipeline information shows that this is now the sole active program, underscoring how much the organization has been pared back around one scientific strategy.
In biotech, a clinical setback often forces a rapid reassessment of spending and staffing. Sionna’s restructuring reflects that pressure, with the company choosing to preserve resources for the programs it still sees as viable.
Cash on hand is expected to last into 2028
As of June 30, Sionna reported an accumulated deficit of $313 million, reflecting significant research, development and manufacturing spending, according to a separate SEC filing. That same filing said the company had $268.3 million in cash at the end of June.
Sionna expects that cash to fund operations into 2028. The company’s restructuring is designed in part to help meet that timeline by reducing spending and keeping the business positioned for its next clinical step.
The figure gives the company room to pursue its narrowed strategy, but it also shows why management moved quickly to cut costs. For a development-stage biotech, cash runway can shape how much science can move forward and how long a company can keep building around a pipeline.
Leadership changes accompany the staff reduction
Along with the layoffs, Sionna terminated the employment of Caroline Stark Beer, its chief business officer, effective Tuesday. The company disclosed that change in its SEC filing tied to the restructuring.
At the same time, the company redistributed some responsibilities rather than replacing those roles outright. McKee’s expanded duties as both chief medical officer and head of R&D suggest Sionna is trying to operate with a leaner management structure as well as fewer employees.
The company did not say whether more leadership changes are planned. For now, the emphasis appears to be on preserving the core team needed to move the dual combination program ahead.
A broader 2026 layoff wave is hitting biopharma
Sionna’s move comes amid a year of deep cost cuts across the biopharma sector. BioSpace’s 2026 layoff tracker shows companies including Merck, Novartis, GSK, TScan Therapeutics and Arsenal Biosciences also cutting staff or restructuring operations.
Many of those changes have been tied to failed trials, cash preservation or a sharper focus on a narrower set of programs. That pattern has become familiar in biotech, where companies often pivot quickly after a setback to protect their most promising assets.
For Sionna, the goal is straightforward: keep the cystic fibrosis effort alive, reduce overhead and buy time for the next round of development. The company’s latest move leaves it smaller, but also more centered on a single path forward.
